The latest news for pharma industry insiders.
Miranda Schmalfuhs
Advertisement
Miranda Schmalfuhs is the associate group social media editor of Pharmaceutical Executive, Pharmaceutical Commerce, and Applied Clinical Trials and can be reached at mschmalfuhs@mjhlifesciences.com.
Articles by Miranda Schmalfuhs
In this part of her Pharmaceutical Executive video interview, Charlotte Owens, MD, FACOG, Head of Medical Affairs and Outcomes Research at Organon, discusses how she's using her in-practice experience as an OB-GYN to inform Organon's strategic approach to addressing maternal health challenges.
The latest news for pharma industry insiders.
In this part of her Pharmaceutical Executive video interview, Charlotte Owens, MD, FACOG, Head of Medical Affairs and Outcomes Research at Organon, identifies Organon's efforts to invest in research, education, and its pipeline to focus on critical areas of need in maternal health.
The latest news for pharma industry insiders.
In this part of her Pharmaceutical Executive video interview, Charlotte Owens, MD, FACOG, Head of Medical Affairs and Outcomes Research at Organon, talks about the most critical to close the gaps in R&D for maternal health solutions and how feasible the fixes are.
The latest news for pharma industry insiders.
In this part of her Pharmaceutical Executive video interview, Charlotte Owens, MD, FACOG, Head of Medical Affairs and Outcomes Research at Organon, discusses the societal implications of maternal health issues both short and long term.
The latest news for pharma industry insiders.
The latest news for pharma industry insiders.
The latest news for pharma industry insiders.
The latest news for pharma industry insiders.
The latest news for pharma industry insiders.
In this part of his Pharmaceutical Executive video interview, Joshua M. Cohen, MD, MPH, FAHS, Chief Medical Officer, Braeburn discusses how the findings from this study contribute to addressing treatment gaps and improving patient outcomes for those struggling with fentanyl dependence, ensuring broader patient access to BRIXADI®, and more.
The latest news for pharma industry insiders.
In this part of his Pharmaceutical Executive video interview, Joshua M. Cohen, MD, MPH, FAHS, Chief Medical Officer, Braeburn discusses data from the Phase III trial recently published in JAMA and how confident they are in the generalizability of these findings to a real-world treatment setting.
The latest news for pharma industry insiders.
The latest news for pharma industry insiders.
The latest news for pharma industry insiders.
In this part of his Pharmaceutical Executive video interview, Fabrice Chouraqui, CEO of Cellarity, discusses some other potential areas where Cellarity's approach could be particularly impactful.
The latest news for pharma industry insiders.
In this part of his Pharmaceutical Executive video interview, Fabrice Chouraqui, CEO of Cellarity, speaks about the broader implications of Cellarity's approach for the drug discovery field.
The latest news for pharma industry insiders.
In this part of his Pharmaceutical Executive video interview, Fabrice Chouraqui, CEO of Cellarity, discusses how their AI/ML approach differs and the advantages it offers in terms of uncovering novel treatment opportunities.
The latest news for pharma industry insiders.
Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
The latest news for pharma industry insiders.
The latest news for pharma industry insiders.
The latest news for pharma industry insiders.
The latest news for pharma industry insiders.
Advertisement
Advertisement
Advertisement
